JP2020511131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511131A5 JP2020511131A5 JP2019548664A JP2019548664A JP2020511131A5 JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5 JP 2019548664 A JP2019548664 A JP 2019548664A JP 2019548664 A JP2019548664 A JP 2019548664A JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- population
- cell according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104262A JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2023204311A JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2024221238A JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2026004149A JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたNK-92 haNK003細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468890P | 2017-03-08 | 2017-03-08 | |
| US62/468,890 | 2017-03-08 | ||
| PCT/US2018/021332 WO2018165291A1 (en) | 2017-03-08 | 2018-03-07 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Division JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたNK-92 haNK003細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511131A JP2020511131A (ja) | 2020-04-16 |
| JP2020511131A5 true JP2020511131A5 (cg-RX-API-DMAC7.html) | 2021-04-08 |
| JP7098648B2 JP7098648B2 (ja) | 2022-07-11 |
Family
ID=63446373
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548664A Active JP7098648B2 (ja) | 2017-03-08 | 2018-03-07 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2024221238A Active JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2026004149A Pending JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたNK-92 haNK003細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2024221238A Active JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたNK-92 haNK003細胞 |
| JP2026004149A Pending JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたNK-92 haNK003細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10801013B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3592845A4 (cg-RX-API-DMAC7.html) |
| JP (5) | JP7098648B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR102769529B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116440293A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018231193B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3053252C (cg-RX-API-DMAC7.html) |
| IL (3) | IL326426A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018165291A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018231193B2 (en) | 2017-03-08 | 2021-07-22 | Immunitybio, Inc. | Modified NK-92 haNK003 cells for the clinic |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| KR20200119892A (ko) * | 2018-10-31 | 2020-10-20 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells) |
| AU2019388876A1 (en) * | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
| WO2020205100A1 (en) * | 2019-03-15 | 2020-10-08 | Nantcell, Inc. | Recombinant eril-15 nk cells |
| US20220265716A1 (en) * | 2019-07-26 | 2022-08-25 | Nantkwest, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| AU2020387167B2 (en) * | 2019-11-20 | 2024-10-24 | Immunitybio, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| WO2021116913A1 (en) * | 2019-12-09 | 2021-06-17 | Nantkwest, Inc. | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| EP4232567A1 (en) * | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| EP4548096A1 (en) * | 2022-06-28 | 2025-05-07 | Cellply S.R.L. | Method for the characterization of products for cell therapy |
| US12681020B2 (en) * | 2024-03-20 | 2026-07-14 | Immunitybio, Inc. | Compositions and methods for NK-92 cells expressing native CD16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997006241A1 (en) * | 1995-08-04 | 1997-02-20 | The General Hospital Corporation | Transgenic swine and swine cells having human hla genes |
| TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| US8034332B2 (en) * | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| CA2289915A1 (en) * | 1997-04-30 | 1998-11-05 | Hans Klingemann | Natural killer cell lines and methods of use |
| DE69834257T2 (de) | 1997-04-30 | 2007-01-04 | Klingemann, Hans | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| CN114533867A (zh) * | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| ES2958720T3 (es) | 2015-06-10 | 2024-02-13 | Immunitybio Inc | Células NK-92 modificadas para tratar el cáncer |
| AU2018231193B2 (en) | 2017-03-08 | 2021-07-22 | Immunitybio, Inc. | Modified NK-92 haNK003 cells for the clinic |
-
2018
- 2018-03-07 AU AU2018231193A patent/AU2018231193B2/en active Active
- 2018-03-07 WO PCT/US2018/021332 patent/WO2018165291A1/en not_active Ceased
- 2018-03-07 CN CN202310355496.3A patent/CN116440293A/zh active Pending
- 2018-03-07 KR KR1020247001475A patent/KR102769529B1/ko active Active
- 2018-03-07 IL IL326426A patent/IL326426A/en unknown
- 2018-03-07 IL IL268617A patent/IL268617B2/en unknown
- 2018-03-07 EP EP18763512.3A patent/EP3592845A4/en active Pending
- 2018-03-07 KR KR1020237015931A patent/KR102626748B1/ko active Active
- 2018-03-07 CN CN201880016940.6A patent/CN110418839B/zh active Active
- 2018-03-07 US US15/914,665 patent/US10801013B2/en active Active
- 2018-03-07 JP JP2019548664A patent/JP7098648B2/ja active Active
- 2018-03-07 KR KR1020257004694A patent/KR20250026391A/ko active Pending
- 2018-03-07 KR KR1020197028804A patent/KR102533061B1/ko active Active
- 2018-03-07 CA CA3053252A patent/CA3053252C/en active Active
-
2019
- 2019-05-28 US US16/424,201 patent/US10774310B2/en active Active
-
2020
- 2020-07-23 US US16/937,370 patent/US11753625B2/en active Active
-
2021
- 2021-09-23 AU AU2021236511A patent/AU2021236511B2/en active Active
-
2022
- 2022-06-29 JP JP2022104262A patent/JP7398518B2/ja active Active
-
2023
- 2023-07-18 US US18/223,338 patent/US12492377B2/en active Active
- 2023-12-04 JP JP2023204311A patent/JP7608580B2/ja active Active
-
2024
- 2024-10-08 IL IL316209A patent/IL316209B2/en unknown
- 2024-12-18 JP JP2024221238A patent/JP7806197B2/ja active Active
-
2025
- 2025-11-10 US US19/385,045 patent/US20260078342A1/en active Pending
-
2026
- 2026-01-14 JP JP2026004149A patent/JP2026063125A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barczak et al. | Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response | |
| CN105658789B (zh) | 干细胞微粒和miRNA | |
| ES2927175T3 (es) | Método de producción de micropartículas | |
| ES2705052T5 (es) | Micropartículas de células madre y ARNmi | |
| SG11202111401RA (en) | Methods and compositions for editing rnas | |
| CN115651927A (zh) | 编辑rna的方法和组合物 | |
| CN118389602B (zh) | 经人工操纵的免疫细胞 | |
| CN104703609A (zh) | 干细胞微粒 | |
| WO2018083700A1 (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| US20210355443A1 (en) | Methods for production of tissue resident memory-like t cells and use thereof | |
| CN104321062A (zh) | 干细胞微粒 | |
| CN108026526A (zh) | 用于改善移植的crispr/cas相关方法和组合物 | |
| JP2016514953A (ja) | テロメア伸長に関する化合物、組成物、方法及びキット | |
| WO2007099534A3 (en) | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same | |
| US12492386B2 (en) | Methods to enrich genetically engineered T cells | |
| JP2024512608A5 (cg-RX-API-DMAC7.html) | ||
| Xiao et al. | Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity | |
| DE60334382D1 (de) | Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen | |
| EP4423280A1 (en) | Method for repairing hair cycle-related genes and method for treating hair cycle-related diseases using mir-520d-5p | |
| IL138615A0 (en) | Alphaviral gene expression system and dna molecules for use therein | |
| CN119836571A (zh) | 用于调节遗传驱动因子的组合物和方法 | |
| Walters et al. | Divergent functions of histone acetyltransferases KAT2A and KAT2B in keratinocyte self-renewal and differentiation | |
| US20240024373A1 (en) | Method to Improve Therapeutic Properties of Stem Cells | |
| Cheng et al. | Canonical Wnt Pathway Enhanced Dental Pulp Mesenchymal Stem Cells‐Mediated Cementum Regeneration | |
| EP3521428A1 (en) | PROMOTER OF Hspa5 GENE |